Last $93.51 USD
Change Today +1.42 / 1.54%
Volume 166.5K
PCRX On Other Exchanges
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

pacira pharmaceuticals inc (PCRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/28/14 - $112.00
52 Week Low
01/6/14 - $54.23
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

pacira pharmaceuticals inc (PCRX) Related Bloomberg News

View More Bloomberg News

pacira pharmaceuticals inc (PCRX) Related Businessweek News

No Related Businessweek News Found

pacira pharmaceuticals inc (PCRX) Details

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products primarily for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company commercializes EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase III clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate, an oncology preclinical candidate, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a development and commercialization agreement, and related supply agreement with Aratana Therapeutics, Inc. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

308 Employees
Last Reported Date: 02/25/14
Founded in 2006

pacira pharmaceuticals inc (PCRX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $916.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $468.4K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $458.9K
Chief Medical Officer
Total Annual Compensation: $367.6K
Principal Accounting Officer and Executive Di...
Total Annual Compensation: $288.4K
Compensation as of Fiscal Year 2013.

pacira pharmaceuticals inc (PCRX) Key Developments

Pacira Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 08:30 AM

Pacira Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 08:30 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Dave Stack, president, chief executive officer and chairman.

Pacira Pharmaceuticals, Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014

Pacira Pharmaceuticals, Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014 . Venue: Convene (Formerly Sentry Centers), 730 3rd Avenue, New York, New York, United States.

Pomerantz LLP Files a Class Action Lawsuit Against Pacira Pharmaceuticals, Inc. and Certain of its Officers

Pomerantz LLP has filed a class action lawsuit against Pacira Pharmaceuticals, Inc. and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-06172, is on behalf of a class consisting of all persons or entities who purchased Pacira securities between April 9, 2012 and September 24, 2014, inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that throughout the class period, Defendants made false and/or misleading statements, and failed to disclose material adverse facts about the company's business, operations, prospects and performance. Specifically, during the class period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the company was overstating the efficacy of its Exparel drug; (ii) the company was improperly promoting its Exparel drug by touting its ability to be effective for up to 72 hours, when in fact, it is only approved for 24 hours of pain relief; (iii) the company improperly claimed that Exparel is safe for use in cholecystectomy and colectomy procedures, when in fact, approved labeling does not provide instructions for, or indicate that Exparel will be safe and effective for postsurgical pain, if used in surgical procedures other than hemorrhoidectomy or bunionectomy; (iv) a substantial portion of the company's revenues were derived from off label marketing; and (v) and as a result of the above, the Company's financial statements were materially false and misleading at all relevant times.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCRX:US $93.51 USD +1.42

PCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $36.91 USD +0.44
Alkermes PLC $57.72 USD +1.56
Cumberland Pharmaceuticals Inc $6.02 USD -0.03
Durect Corp $0.80 USD -0.0133
Halyard Health Inc $41.71 USD -0.91
View Industry Companies

Industry Analysis


Industry Average

Valuation PCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.8x
Price/Book 21.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIRA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at